ECMOLife – Eurosets Announces Full Commercial Release

ECMOlife system for ExtraCorporeal Life Support (ECLS) release comes after a successful pre-market clinical evaluation in which critically ill patients were supported by the device for a cumulative period of over 400 days with the longest individual treatment lasting 27 days.

ECMOlife expands Eurosets’ portfolio to provide temporary support to patients in different therapeutic areas, including ExtraCorporeal Membrane Oxygenation (ECMO) and Mechanical Circulatory Support (MCS). These therapies are used to treat patients suffering from ventricular disease, cardiac arrest or respiratory failure resulting from acute respiratory distress syndrome (ARDS), H1N1, SARS, or COVID-19 infections.

ECMOLife is a life-saving device that is able to temporarily replace the functions of severely compromised heart and lungs. The device acts as an external artificial organ connected to the patient through the main blood vessels and is used in cases where pharmacological therapy is considered insufficient.

Featuring a magnetic-levitating centrifugal pump, optimal performance and enhanced biocompatibility, ECMOlife is the most gentle, safe and versatile solution for ECLS. It is also the only device available on the market with an integrated backup system, ensuring greater patient safety and easier management for healthcare professionals even during extra-hospital transports.

ECMOlife underwent a pre-market evaluation across nine centers in Europe. The device was adopted for treatment of critically ill Covid-19 patients when mechanical ventilation was unsuccessful, as well as patients suffering from post-cardiotomy cardiogenic shock, undergoing lung transplant or requiring cardiopulmonary assistance.

One of the first centers to use ECMOlife was the University Hospital of Brussels. The ECLS team, led by Prof. Dr. Meir, Head of Cardiac Surgery, Prof. Dr. De Waele, Head of the ICU and Dr. Kurt Staessens, Head of the Cardiovascular Perfusion Group, reported about their experience: “We are really pleased with the performance of ECMOLife. The magnetic levitation technology can reduce the level of hemolysis and the risk of thrombus generation. In addition, the non-invasive monitoring system combined with the unique integrated backup unit may improve patient care, ensuring additional safety in the event of an emergency”.

“Our mission is to offer new solutions to patients who do not benefit from traditional therapies and ECMOLife is fully in line with these core beliefs”, said Antonio Petralia, Executive Vice President & CEO of Eurosets. “Our device supported critically ill patients for 6 months since its pre-market clinical evaluation release in Europe and we are now very proud to have it fully available to help patients and clinicians worldwide.”

 

SourceEurosets
Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

The ArthroFree system is the first FDA-cleared wireless camera for arthroscopy and general endoscopy, both areas of minimally invasive surgery. The system is designed to help surgeons work with aximum dexterity and focus.
The project, which was led by the University of Southern California, included large increases in representation among men of African, Hispanic and Asian ancestries, that were contributed in part by an ongoing collaboration between the U.S. Department of Veterans Affairs and DOE reports Argonne.
This innovative software turns smartphones into medical-grade stethoscopes, allowing people to capture, analyze, and share critical heart health data with medical personnel from the comfort of any location notes Sparrow BioAcoustics.
"Taewoong Medical becoming an Olympus group company is also a major milestone in our global growth strategy," said Henry Shin, CEO of STARmed. "We look forward to our products being made available to more patients through Olympus' global distribution network."
The company reports they have successfully met the six-month primary endpoint for the first-ever female patient implanted with the UroActive™ System, the first smart automated artificial urinary sphincter (AUS) to treat SUI.

By using this website you agree to accept Medical Device News Magazine Privacy Policy